



3401 Princeton Pike, Lawrenceville, NJ 08648

NOTIFICATION OF SUPPLY ALLOCATION: VIDAZA® (azacitidine)
May 01, 2020

This notice provides information for 340B covered entities that Celgene Corporation ("Celgene"), a subsidiary of Bristol-Myers Squibb, markets VIDAZA® (azacitidine) (for subcutaneous or intravenous use) ("VIDAZA"):

Product	Description	NDC NUMBER
VIDAZA® (azacitidine)	Lyophilized powder in 100 mg single-dose vial	59572-102-01

VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML).

Due to an increase in demand, Celgene is experiencing global supply constraints for VIZADA. To minimize disruption to patient care and address the current imbalance between supply and increasing demand, we will be proportionally allocating the medicine across countries where Celgene is the sole or primary supplier, including the United States. Limitations on purchasing of VIDAZA in the United States will be proportional and non-discriminatory for all customers, including 340B covered entities.

Beginning May 1, 2020, Celgene will only accept direct purchases under the allocation model. Celgene will allow each direct customer (including each wholesaler and distributor) to purchase a specified percentage of its historical purchase volume of VIDAZA, based on average utilization between January and March 2020. The specified allocation percentage will be determined by Celgene based on available supply and will apply equally to all direct customers. Celgene will then direct wholesalers and distributors to allocate their inventory of VIDAZA based on the specified allocation percentage as applied to each customer's historical purchasing patterns. Celgene will allocate VIDAZA to direct purchasers in a one-month supply. The same allocation procedure will apply to both 340B-covered entities and non-340B customers. Celgene will continue to make VIDAZA available to covered entities at a price no higher than the statutorily calculated ceiling price. Celgene anticipates that this allocation program will stay in place for the remainder of 2020, when it will be reassessed and any changes to the allocation program will be communicated at that time.

Celgene takes its obligations under the 340B program seriously and will make every effort to ensure that VIDAZA is available to 340B covered entities in a manner that is no more restrictive than it is for non-340B customers.

If you have any questions regarding this program, please call 1-888-423-5436 from 8AM to 8PM ET, Monday through Friday (except holidays).